Comparative Pharmacology
Head-to-head clinical analysis: DEXMETHYLPHENIDATE HYDROCHLORIDE versus QUILLIVANT XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXMETHYLPHENIDATE HYDROCHLORIDE versus QUILLIVANT XR.
DEXMETHYLPHENIDATE HYDROCHLORIDE vs QUILLIVANT XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexmethylphenidate is a central nervous system (CNS) stimulant. Its mechanism of action in ADHD is not fully understood, but it is believed to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space.
Extended-release oral suspension formulation of methylphenidate, a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their synaptic concentrations. The exact therapeutic effect in ADHD is unknown but is thought to involve dopaminergic and noradrenergic pathways in the prefrontal cortex.
Initial: 5 mg orally twice daily (morning and noon) with or without food; titrate in increments of 5 mg weekly; maximum 20 mg twice daily (40 mg/day).
Initial: 25 mg orally once daily in the morning; may increase weekly in 25 mg increments based on tolerability and response. Maximum: 75 mg once daily.
None Documented
None Documented
2-4 hours (immediate-release); 4-5 hours (extended-release); clinical context: short half-life necessitates multiple daily dosing for immediate-release formulations
Approximately 4 hours; extended-release formulation provides therapeutic levels for ~12 hours.
Renal (78-97% as metabolites and unchanged drug, with approximately 50% as de-esterified metabolites and 30% as unchanged drug)
Primarily renal (approximately 60% as unchanged drug); fecal excretion accounts for <5%.
Category A/B
Category C
CNS Stimulant
CNS Stimulant